| Page 46 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)

Author(s): 
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert
Primary Author: 
Malcovati L
Journal Title: 
Blood
Original Publication Date: 
Apr 2020

The 2016 revision of the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues is characterized by a closer integration of morphology and molecular genetics. Notwithstanding, the myelodysplastic syndrome (MDS) with isolated del(5q) remains so far the only MDS subtype defined by a genetic abnormality.

Bone Marrow Disease(s): 

Common Questions and Answers About COVID-19 for Older Adults and People with Chronic Health Conditions

According to the United States Centers for Disease Control and Prevention (CDC), coronaviruses are a large family of viruses that are common in humans and can cause illnesses ranging from mild respiratory infections like the common cold to serious illnesses, such as pneumonia or Severe Acute Respiratory Syndrome (SARS). The novel coronavirus (COVID-19) has now been detected in more than 100 countries, including the US.
Why are older adults and people with chronic health conditions at higher risk?

AAMDSIF Podcast for Patients: Dr. Amit Verma discusses approval of Luspatercept for certain MDS patients

Here is a discussion of the recent approval of Luspatercept with Dr. Amit Verma, Director of the Division of Hematologic Malignancies and a Professor of Oncology at the Albert Einstein College of Medicine in New York City. He explains the results of clinical trials and describes which MDS patients have the best response to this medication.

 #MDS #treatingMDS